Destiny Pharma
      
Skip to content
  • About Us
    • Board of Directors
    • Leadership
    • Scientific Advisory Board
    • Our Values
    • History
  • Pipeline
    • NTCD-M3 for Clostridioides difficile Infections
    • XF-73 Nasal for Post Surgical Infections
    • XF-73 for Dermal Infections
    • SPOR-COV™ for COVID-19
    • XF Research Programs
  • Target Markets
    • Clostridioides difficile Infections
    • Post Surgical Infections
    • Dermal Infections
    • COVID-19
    • Anti-Microbial Resistance
  • Our Technologies
    • Biotherapeutics
      • NTCD-M3
      • SPOR-COV™
    • XF Platform
  • Business Development
  • News and Media
    • Media
    • Events
  • Investors
    • AIM Rule 26
    • Corporate Governance
    • Share Price Information
    • Regulatory News
    • Constitutional Documents
    • Reports & Presentations
    • Advisers / Shareholder Contacts
    • Analyst Coverage
    • Email Alerts
  • Careers
  • Contact

08 September 2022 – Interim results for six months ended 30 June 2022

Posted on 08/09/2022 by Kirsty Richardson

Destiny Pharma today announced its interim results for the 6 months ended 30 June 2022, which can be found here.

Categories : News Press Release
Bookmark the permalink

Post navigation

Previous Post07 September 2022 – Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference
Next Post22 September 2022 – Notice of R&D Update Meeting

Categories

  • Categories
    • Events
    • News
    • Old Events
    • Press Release
    • Regulatory News
    • Uncategorised

    • Archives

    • March 2023
    • February 2023
    • January 2023
    • December 2022
    • November 2022
    • October 2022
    • September 2022
    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • March 2022
    • February 2022
    • January 2022
    • December 2021
    • November 2021
    • October 2021
    • September 2021
    • August 2021
    • July 2021
    • June 2021
    • May 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • November 2018
    • October 2018
    • September 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018
    • December 2017
    • October 2017
    • September 2017
    • August 2017
    • July 2017
    • June 2017
    • May 2017
    • April 2017
    • March 2017
    • February 2017
    • December 2016
    • November 2016
    • October 2016
    • September 2016
    • August 2016
    • July 2016
    • May 2016
    • March 2016
    • January 2016
    • November 2015
    • October 2015
    • August 2015
    • June 2015
    • May 2015
    • March 2015
    • February 2015
    • January 2015
    • December 2014
    • November 2014
    • October 2014
    • September 2014
    • August 2014
    • July 2014
    • April 2014
    • January 2014
    • December 2013
    • November 2013
    • September 2013
    • May 2013
    • March 2013
    • February 2013
    • January 2013
    • October 2012
    • July 2012
    • March 2012
    • November 2011

    Destiny Pharma

    © All rights reserved.

    Powered by WordPress

    Destiny Pharma plc
    Sussex Innovation Centre
    Science Park Square
    Brighton
    BN1 9SB
    UK

    Tel: +44(0) 1273 704440

    Registered Company
    No. 3167025
    About Us
    Pipeline
    Target Markets
    Our Technologies
    Business Development
    News
    Investors
    Contact
    Terms of Use
    Privacy Statement